Barclays’s Enzo Biochem, Inc. ENZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,989
| Closed | -$21K | – | 4822 |
|
|
2021
Q3 | $21K | Buy |
5,989
+908
| +18% | +$3.03K | ﹤0.01% | 4384 |
|
|
2021
Q2 | $16K | Sell |
5,081
-32,057
| -86% | -$101K | ﹤0.01% | 4549 |
|
|
2021
Q1 | $128K | Buy |
37,138
+16,037
| +76% | +$49.9K | ﹤0.01% | 3901 |
|
|
2020
Q4 | $53K | Buy |
21,101
+826
| +4% | +$1.8K | ﹤0.01% | 4379 |
|
|
2020
Q3 | $42K | Sell |
20,275
-4,087
| -17% | -$9.71K | ﹤0.01% | 4685 |
|
|
2020
Q2 | $54K | Buy |
24,362
+9,754
| +67% | +$25.1K | ﹤0.01% | 4899 |
|
|
2020
Q1 | $37K | Sell |
14,608
-30,371
| -68% | -$74.6K | ﹤0.01% | 5395 |
|
|
2019
Q4 | $118K | Buy |
44,979
+22,067
| +96% | +$65.9K | ﹤0.01% | 5384 |
|
|
2019
Q3 | $82K | Sell |
22,912
-6,453
| -22% | -$22.8K | ﹤0.01% | 5624 |
|
|
2019
Q2 | $99K | Buy |
29,365
+16,919
| +136% | +$59.6K | ﹤0.01% | 5703 |
|
|
2019
Q1 | $34K | Buy |
12,446
+12,384
| +19,974% | +$40.5K | ﹤0.01% | 6123 |
|
|
2018
Q4 | $0 | Sell |
62
-17,040
| -100% | -$55.8K | ﹤0.01% | 7419 |
|
|
2018
Q3 | $70K | Buy |
17,102
+13,878
| +430% | +$63K | ﹤0.01% | 5850 |
|
|
2018
Q2 | $16K | Sell |
3,224
-7,310
| -69% | -$44.5K | ﹤0.01% | 6315 |
|
|
2018
Q1 | $59K | Sell |
10,534
-8,595
| -45% | -$60.5K | ﹤0.01% | 5792 |
|
|
2017
Q4 | $156K | Buy |
19,129
+972
| +5% | +$9.28K | ﹤0.01% | 4900 |
|
|
2017
Q3 | $191K | Sell |
18,157
-14,677
| -45% | -$163K | ﹤0.01% | 4470 |
|
|
2017
Q2 | $361K | Buy |
32,834
+11,288
| +52% | +$105K | ﹤0.01% | 3841 |
|
|
2017
Q1 | $181K | Sell |
21,546
-57,454
| -73% | -$405K | ﹤0.01% | 4418 |
|
|
2016
Q4 | $548K | Sell |
79,000
-6,144
| -7% | -$39.2K | ﹤0.01% | 3290 |
|
|
2016
Q3 | $433K | Buy |
85,144
+24,464
| +40% | +$146K | ﹤0.01% | 3347 |
|
|
2016
Q2 | $362K | Buy |
60,680
+1,380
| +2% | +$7.66K | ﹤0.01% | 3477 |
|
|
2016
Q1 | $237K | Buy |
59,300
+59,236
| +92,556% | +$264K | ﹤0.01% | 3722 |
|
|
2015
Q4 | $0 | Sell |
64
-7,036
| -99% | -$29.7K | ﹤0.01% | 6675 |
|
|
2015
Q3 | $21K | Buy |
+7,100
| New | +$21.5K | ﹤0.01% | 5446 |
|
|
2015
Q2 | – | Sell |
-1,163
| Closed | -$2K | – | 7247 |
|
|
2015
Q1 | $2K | Sell |
1,163
-929
| -44% | -$3.04K | ﹤0.01% | 6892 |
|
|
2014
Q4 | $8K | Sell |
2,092
-151
| -7% | -$720 | ﹤0.01% | 6833 |
|
|
2014
Q3 | $12K | Buy |
2,243
+1,461
| +187% | +$7.79K | ﹤0.01% | 6792 |
|
|
2014
Q2 | $4K | Buy |
782
+708
| +957% | +$3.06K | ﹤0.01% | 7211 |
|
|
2014
Q1 | $0 | Sell |
74
-26,096
| -100% | -$89.4K | ﹤0.01% | 7742 |
|
|
2013
Q4 | $52K | Buy |
26,170
+19,580
| +297% | +$48.6K | ﹤0.01% | 6162 |
|
|
2013
Q3 | $13K | Sell |
6,590
-5,655
| -46% | -$13.4K | ﹤0.01% | 6706 |
|
|
2013
Q2 | $25K | Buy |
+12,245
| New | +$27K | ﹤0.01% | 6727 |
|
Other funds holding ENZ
HFA
RAM
VCA
AE
Barclays's ENZ Position: Q4 2021 in Review
Barclays sold out of Enzo Biochem, Inc. (ENZ) in Q4 2021, closing a stake of 5,989 shares — an estimated $21K sold.
Barclays first reported a position in ENZ in Q2 2013 and held it in 33 quarters. The position peaked at $548K in Q4 2016. 59 funds tracked by Wall St. Rank hold ENZ as of Q4 2021.
- Barclays reported no remaining Enzo Biochem, Inc. position as of Q4 2021 after selling out during the quarter.
- Barclays sold 5,989 Enzo Biochem, Inc. shares in Q4 2021, an estimated $21K.
- Barclays first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 33 quarters.
- Barclays's Enzo Biochem, Inc. position peaked at $548K in Q4 2016.
- 59 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.